AnaptysBio (ANAB) Revenue by Segment

Revenue split across business segments, revealing whether income is coming from partnerships, licensing milestones, or any product sales. For AnaptysBio, a reliance on collaboration or milestone payments indicates limited commercial revenue and higher revenue concentration risk, while diversified or growing segment revenues signal progress toward a more predictable business model. Helps gauge near-term cash visibility and dependency on partner deals.

All reported revenue is coming from Royalty Management while Biopharma shows no product revenue, indicating the company is monetizing IP through licensing/royalties rather than commercializing its own drugs. That provides near-term cash visibility but creates concentration and counterparty risk—future topline depends on partner sales and milestone timing, not internal commercialization. Investors should watch royalty terms, partner performance, and any new licensing or clinical-readout milestones that would diversify and re‑accelerate revenue.